Phase 3 N=96 Randomized Double-blind Treatment

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Mucopolysaccharidosis II

Bottom Line

View on ClinicalTrials.gov: NCT00069641 ↗

Enrolled (actual)

Serious AEs

27.1%

Results posted

May 2015

Primary outcome: Primary: Ranked Adjusted 2-Component Composite Variable Score Based on Change From Baseline to Week 53 — 69.81; 50.86 sum of the ranked scores — p=0.0049

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Iduronate-2-sulfatase enzyme replacement therapy (Biological); Placebo (Biological)
Age: Pediatric, Adult · 5+ yrs
Sex: Male
Sponsor: Shire
Primary completion: Mar 2005

Outcome Measures

Outcome	Result	p-value
PRIMARY Ranked Adjusted 2-Component Composite Variable Score Based on Change From Baseline to Week 53	69.81; 50.86	0.0049 sig
SECONDARY Change From Baseline in Mean Global Joint Range of Motion (JROM) Score at Week 53	66.86; 67.36; 67.70; 0.89; -0.61; 0.70	—
SECONDARY Mean Combined Liver and Spleen Volume at Baseline	1578.48; 1442.2; 1485.28	—
SECONDARY Percent Change From Baseline in Mean Combined Liver and Spleen Volume at Week 53	-25.81; -23.73; 0.27	—
SECONDARY Change From Baseline in Mean Normalized Urine Glycosaminoglycan (GAG) Levels at Week 53	325.59; 338.08; 419.40; -189.23; -154.98; 18.16	—
SECONDARY Mean Cardiac Left Ventricular Mass Index (LVMI) at Baseline	105.18; 89.42; 95.55	—
SECONDARY Percent Change From Baseline in Mean Cardiac Left Ventricular Mass Index (LVMI) at Week 53	-1.34; 6.71; 3.56	—

Summary

The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.

Eligibility Criteria

Inclusion Criteria

To be eligible to participate in this study, patients must meet the following inclusion criteria prior to enrollment:

The diagnosis of MPS II will be determined by the investigator based upon both clinical and biochemical criteria.
All patients must have at least one of the following Clinical Criteria considered by the investigator to be MPS II-related:
Hepatosplenomegaly
Radiographic evidence of dysostosis multiplex
Valvular heart disease
Evidence of obstructive pulmonary disease
In addition, patients must have the following Biochemical Criteria:
Documented deficiency in iduronate-2-sulfastase enzyme activity of less than or equal to 10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).
A normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).
Must be male, 5 to 25 years of age.
Forced vital capacity of <80% of predicted obtained at the baseline evaluation of this study.
Must be able to adequately perform the testing required in this study, including reproducible pulmonary function testing by spirometry, as judged by the investigator.
Patient, patient's parent(s), or legally authorized guardian must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.

Exclusion Criteria

Patients meeting any of the following criteria are not eligible for participation in this study:

Patient has received treatment with another investigational therapy within the past 60 days.
Patient, patient's parent(s), or patient's legal guardian is unable to understand the nature, scope, and possible consequences of the study.
Patient is unable to comply with the protocol (e.g., due to a medical condition such as cervical cord compression or uncooperative attitude) or is unlikely to complete the study, as determined by the investigator.
Patient has a tracheostomy.
Patient has received a bone marrow or cord blood transplant.
Patient with known hypersensitivity to any of the components of iduronate-2-sulfatase.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00069641). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.